Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Agrees To Roll Back Prices On 40 Drugs, Yielding To Pressure From Trump

Executive Summary

After a conversation with President Trump, CEO Ian Read agreed to cancel price increases on 40 drugs that took effect July 1, to give the administration time to work on its blueprint for improving the health care system.

Advertisement

Related Content

The Inevitable Is Coming: Price Increases, Starting With Pfizer
On Drug Price Increases, Pfizer's Read Expects ‘Business As Normal’ In 2019
10 Things For Pfizer's New CEO To Worry About
Pfizer Expects Rebate Reform By HHS Will Extend Quickly To Private Market
States Take Center Stage In Tackling Rx Drug Pricing
Who's Promised What: A Guide To Pharma Drug Pricing Pledges
Penny For Your Thoughts? HHS Secretary Azar’s Blunt Words For 340B Providers
US Senators Seek 'Clarity’ On Middlemen Obstructing List Price Reductions
Big Pharma Voluntary List Price Reductions Doubtful, Sen. Warren Says

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS123463

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel